Austin, Texas-based Bioo Scientific Corporation has launched a campaign to develop and optimize automation protocols for the Sciclone NGS and NGSx Workstations in order to increase scientific productivity in research with the same quality of results. This project was undertaken to help develop and promote innovative solutions for the life science industry.
The optimized automation protocols were developed by Bioo Scientific for the NEXTflex library preparation kits, and include the NEXTflex Rapid Directional qRNA-Seq Kit, the NEXTflex Rapid Directional RNA-Seq Kit, the NEXTflex Rapid RNA-Seq Kit and the NEXTflex Rapid DNA-Seq Kit. The protocols are designed to help advance the research process using these tools.
Bioo Scientific is making the automated protocols available to their customers to help them avoid library preparation bottlenecks and incorporate novel bias-reducing technologies, extensive multiplexing capabilities, speed and flexibility.
The company is currently developing and commercializing a portfolio of products designed to decrease bias while increasing sensitivity, flexibility and acceleration of next-generation sequencing, in which a growing series of automated methods for NGS sample preparation are included. Bioo’s products are commercialized in over 100 countries either directly or through its global distribution network.
Last year, the company announced that it would start offering a new set of ELISA tests for the detection of Epizootic Hemorrhagic Disease Virus (EHDV), an orbivirus that infects most wild and domestic ruminants. The new exam was designed to test white-tailed deer in North America, as EHDV is endemic in North America among the white-tailed deer population.
Bioo has launched two kits, the NovareDx EHDV Detection Kit for the detection of EHDV antigen, which is optimal for early detection of the virus, as well as the NovareDx EHDV Antibody Test Kit, which accurately detects EHDV antibodies. At the same time, the company continues to remain highly active in fields related to the company’s portfolio of technologies that focus on RNAi agent delivery technology, drug technologies and test kit products.
In addition, the biotech’s range of business is so wide that it has already served as a training site for implementing services in lateral flow, ELISAs, and enzymatic assays to a delegation from Turkmenistan from the Cochran Fellowship Program. The aim of the fellowship program is to provide training and cooperation to professionals from emerging markets, emerging democracies, and middle-income countries in the agriculture and agribusiness fields.